Prothena reveals positive amyloidosis data; CEO's cancer
This article was originally published in Scrip
Elan spinout Prothena said after the stock market closed on 2 December that interim Phase I/II results for NEOD001 in the treatment of amyloidosis justify initiation of a Phase III clinical trial, but the company's stock closed down 5% at $21.99 on 3 December after CEO Dale Schenk revealed that he has pancreatic cancer.
You may also be interested in...
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.